Eloralintide ETA?

L

LabBetter

Well-known member
Eloralintide (LY3841136) is being called EL's answer to NN's Cagrilintide and ZP's Petrelintide, since it's an amylin analogue. Apextide seems to be the main manufacturer, linked to Sinopep. Anyone have insights on when it might become available for independent research?
 
Cagrilintide, Petrelintide, and Eloralintide work by mimicking amylin, not GLP-1/GIP/Glucagon. SinoPep is a pretty big peptide manufacturer that's FDA approved, too.
 
If I remember correctly, Elora doesn't have the pH issues some other compounds have. So hopefully it'll be available pretty quickly? (Though maybe Cagri doesn't either, still not confirmed)
 
Evil Lilly's CEO has mentioned they have a total of eleven different weight loss peptides in active research. So many new compounds are coming, stuff we haven't even heard whispers about yet.
 
And that's just EL... Imagine how many of the known and unknown compounds will actually get approved, and how long it will take. I guess a rational person would wait and only worry about things on the pharmacy shelf, but I am not that person. So, here I am, poking around in things that don't really concern me.
 
I think a Tirz/Reta plus an amylin agonist is probably the best combo for weight loss in the near future. EL probably thinks so too, and the reports on Tirz/Cagri stacks are interesting. CagriSema is essentially already doing this, and others will follow.
 
Just a heads up: historically, only about 35% of drugs in phase two trials make it to phase three.

That's because not all new drugs are safe, or the side effects are too severe, or there are other problems that cause them to fail in phase two.

Even drugs that progress to phase three may not be approved for general use.

Many drugs/compounds fail, whether it's due to safety issues, lack of effectiveness, or other concerns like potential links to cancers.

Clinical studies take a long time for a reason.

I hope elora succeeds and proves to be safe, effective, and with minimal side effects. That's the holy trinity for any new drug. If it's lacking in any of those three, it's a failure.
 
I have a friend in the current study. They kept her at the lowest dose, and she had extreme fatigue and her weight loss stopped after 3 months. Maybe the results are better at higher doses.
 
Thanks for the info! Lots of Cagri research shows significant side effects and variable dose tolerance. Might be common with amylin analogs. I'll be interested in hearing how your friend does.
 
You must log in or register to reply here.
Back
Top